Bioverativ Therapeutics Inc. competitive analysis

Explore patent oppositions filed by Bioverativ Therapeutics Inc. against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
Sodium Chloride Solution For Drug Reconstitution Or DilutionWYETHMay 14, 2020
Compositions And Methods For Enhancing Coagulation Factor Viii FunctionTHE CHILDRENS HOSPITAL OF PHILADELPHIAAug 21, 2019

Explore Bioverativ Therapeutics Inc.'s recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
Jan 24, 2024Optimized Factor Viii Gene1
Jun 29, 2022Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses Thereof2

Latest PTAB cases involving Bioverativ Therapeutics Inc.

Discover the latest PTAB cases involving Bioverativ Therapeutics Inc., highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 27, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Bioverativ Therapeutics Inc.

IPR2018-01345Jul 6, 2018CSL BEHRINGBIOVERATIV THERAPEUTICS INC.Institution Denied
IPR2018-01345Jul 6, 2018CSL BEHRING GMBHBIOVERATIV THERAPEUTICS INC.Institution Denied
IPR2018-01313Jul 2, 2018CSL BEHRINGBIOVERATIV THERAPEUTICS INC.Institution Denied
IPR2018-01313Jul 2, 2018CSL BEHRING GMBHBIOVERATIV THERAPEUTICS INC.Institution Denied

Peer Comparison New

IP litigation analysis comparing Bioverativ Therapeutics Inc. with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIOVERATIV THERAPEUTICS INC.23 - 2
CSL BEHRING - 74 -
CSL BEHRING GMBH334 -
EUROPEAN OPPOSITIONS30 - - -